Related Experiment Video
Updated: Sep 23, 2025
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
HDL Mimetic Peptides
Jie Chen1, Jiewen Liu2, Baoqi Yu3,4,5
1The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China.
Insights
HDL mimetic peptides offer a new therapeutic approach for cardiovascular disease (CVD) by improving HDL function, not just levels. These peptides show promise in preventing atherosclerosis by enhancing cholesterol removal and natural HDL function.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Pharmacology
Background:
- Therapeutic strategies targeting high-density lipoprotein (HDL) levels have not yielded expected cardiovascular disease (CVD) outcomes.
- Improving HDL function, rather than solely increasing plasma levels, is a new focus in CVD research.
- HDL mimetic peptides are being investigated as a novel therapeutic avenue.
Purpose of the Study:
- To review recent studies on the roles and potentials of HDL mimetic peptides.
- To explore the therapeutic applications of HDL mimetic peptides in atherosclerosis-related CVD.
- To understand the mechanisms and antiatherogenic effects of HDL mimetic peptides.
Main Methods:
- Review of recent scientific literature on HDL mimetic peptides.
- Analysis of studies investigating HDL mimetic peptides in animal models.
- Examination of the effects of HDL mimetic peptides on reverse cholesterol transport (RCT) and HDL function.
Main Results:
- HDL mimetic peptides demonstrate antiatherogenic effects.
- These peptides can accelerate reverse cholesterol transport (RCT).
- They improve natural HDL function without necessarily increasing HDL plasma levels.
Conclusions:
- HDL mimetic peptides show a promising therapeutic role in preventing atherosclerosis and related CVD.
- Further research into the mechanisms of HDL mimetic peptides is warranted.
- HDL mimetic peptides represent a potential new strategy for managing cardiovascular diseases.
Abstract:
Since therapeutic strategies designed to raise HDL failed to exert the expected effective cardiovascular disease (CVD) outcomes in clinical trials, how to improve HDL function rather than its plasma level has become a new focus of scientists' attention. Numerous HDL mimetic peptides have been designed and investigated in various animal models in recent years. Although the underlying mechanisms are not fully understood, the peptides' antiatherogenic effects, such as acceleration of RCT and improvement of natural HDL function without necessarily raising its level, showed a promising therapeutic role in the prevention of atherosclerosis and other diseases. This chapter reviews recent studies on the roles and potentials of HDL mimetic peptides in atherosclerosis-related CVD.
